Mangalam Drugs And Organics Limited (MANGALAM) — Board Meeting

1 Board Meeting 🟡 Notable Neutral 📄 PDF

📢 Key Event
Board approved resignation of Company Secretary Anuradha Pandey and appointment of Shweta Patel as replacement.

🔄 What Changed
Company Secretary position transitions from Anuradha Pandey (departing March 29, 2026) to Shweta Patel (joining April 19, 2026). New appointee has 3 years of corporate compliance experience.

🔮 What's Next
Shweta Patel's appointment effective April 19, 2026. Anuradha Pandey's last working day: March 29, 2026.

💡 Investor Takeaway
Routine management succession with minimal operational impact; new appointee has relevant compliance credentials to maintain regulatory standards.

Mangalam Drugs and Organics Limited's Board approved two key changes in the Company Secretary & Compliance Officer position on March 26, 2026. Ms. Anuradha Pandey resigned effective March 29, 2026, to pursue external opportunities. Ms. Shweta Patel, an Associate Member of the Institute of Company Secretaries with 3 years of compliance experience, was appointed as her successor effective April 19, 2026. The transition maintains regulatory compliance oversight during the handover period.

2 Board Meeting 🟡 Notable Neutral 📄 PDF

📢 Key Event
Company Secretary resignation accepted; replacement appointed.

🔄 What Changed
Ms. Anuradha Pandey (outgoing) replaced by Ms. Shweta Patel (incoming, age 27, B.Com, 3 years experience as Company Secretary).

🔮 What's Next
Ms. Patel's appointment effective April 1, 2026; Ms. Pandey's last working day March 29, 2026.

💡 Investor Takeaway
Routine management transition with no business disruption; new CS has relevant compliance credentials for a WHO-GMP pharma company.

Mangalam Drugs and Organics Limited's Board approved personnel changes on March 26, 2026. Ms. Anuradha Pandey resigned as Company Secretary & Compliance Officer effective March 29, 2026, citing pursuit of external opportunities. Ms. Shweta Patel, an Associate Member of the Institute of Company Secretaries with 3 years' experience, was appointed as replacement effective April 1, 2026. The transition involves routine compliance officer duties with no disclosed financial or operational impact.